Inovio is bringing IMMUNO-INGENUITY to life and reshaping the future of treating and preventing cancer and infectious diseases.
Potential HPV Immunotherapy Treatment:
Global Phase III
Clinical Trial - HPV301: Revealing New Treatment Possibilities
Leading the way in activation immunotherapy
Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)
“At Inovio, the revolutionary power of our technology is superseded only by the dedication, passion, and expertise of the team we have brought together to bring our technology to life for patients in need.”
J. Joseph Kim, Ph.D.
President and CEO
Inovio's technology is IMMUNO-INGENUITY in action
Inovio's activation immunotherapy platform is generating best-in-class immune responses in the fight against cancer and infectious diseases.